Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Austin, Texas--(Newsfile Corp. - April 23, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command's (NMRC) Deployment Associated Infections Division (DAID) laboratory to conduct in vitro testing of Claromers™ for treatment and prevention of diarrheal illness. This agreement marks the 7th signed U.S. military agreement for Maxwell.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/9658/249227_3f91d82d3479fba4_001.jpg ]
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9658/249227_3f91d82d3479fba4_001full.jpg
Diarrheal diseases remain the most pervasive infectious threat to U.S. military operational readiness [ 1 ]. The majority of cases result from increasingly drug-resistant strains of bacteria causing debilitating outbreaks that cripple mission effectiveness. During Operation Iraqi Freedom (OIF), 76% of warfighters experienced diarrheal episodes. Diarrheal diseases outpaced respiratory illnesses and injuries as the top non-combat medical issue [ 2 ].
In field conditions, even a single episode of diarrhea can sideline a soldier for days, impairing unit performance and mission success. 80% of cases require antibiotics or IV fluids [ 3 ]. Chronic post-infection complications like irritable bowel syndrome (15-30% of cases) and reactive arthritis further degrade long-term readiness [ 4 ].
As antibiotic resistance continues to rise, traditional treatments are losing efficacy, making preventive options and new therapeutic approaches an urgent priority. The impact isn't limited to the battlefield: travelers, humanitarian responders and civilians in low-resource settings also face similar risks, underscoring the need for globally relevant solutions.
'This partnership isn't just about stopping pathogens; it's about keeping our forces mission-ready and preventing critical situations from going down the drain. With Claromers™, we're determined to flush out antibiotic resistance and ensure troops aren't bogged down by debilitating illnesses,' said Scotch McClure, Founder & CEO of Maxwell Biosciences.
About NMRC
NMRC, headquarters of Navy Medicine Research & Development, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps, and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology.
About DAID
Part of NMRC's Operationally Relevant Infections Department, DAID focuses on the advancement of both prophylactic vaccine and immunoprophylaxis products against Campylobacter, ETEC and Shigella mediated diseases that affect the warfighter.
About Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, pan-coronavirus and pan-Influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new 'One Drug for Many Bugs' technology has been shown to be well-tolerated in lab-grown human tissues and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives.
For more information, visit MaxwellBiosciences.com, or follow us on X and LinkedIn.
Contacts
Media
[email protected]
Investors
[email protected]
Disclaimer
The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249227
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
2 days ago
- Hamilton Spectator
VERSES® Featured in IEEE Spectrum
VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ('VERSES'' or the 'Company'), a cognitive computing company specializing in next-generation agentic software systems, has been featured in IEEE Spectrum, the flagship publication of the IEEE, the world's largest professional organization devoted to engineering and the applied sciences. The article, co-authored by VERSES CEO Gabriel René, addresses questions such as: Why does the Spatial Web matter? How, exactly, can it make the world better? These are answered with five example use cases for the Spatial Web: VERSES CEO Gabriel René said 'I am delighted to see our vision of the Spatial Web in IEEE Spectrum. These standards will make it easier for our product, Genius™, to interconnect a physical world-full of devices, phones, wearables, robots, drones, and even AI agents. For Genius customers, this can mean quicker development and deployment and lower integration costs.' The article can be found at: About VERSES VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at , LinkedIn and X . On behalf of the Company Gabriel René, Founder & CEO, VERSES AI Inc. Press Inquiries: press@ Investor Relations Inquiries James Christodoulou, Chief Financial Officer IR@ , +1(212)970-8889
Business Wire
2 days ago
- Business Wire
Bradford Health Services Earns Coveted "Great Place To Work"® Certification
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Bradford Health Services, a leading provider of drug and alcohol addiction treatment across the Southeastern U.S., today announced it has been officially certified as a Great Place To Work®. This recognition, awarded by the global authority on workplace culture, underscores Bradford Health's commitment to building a supportive, inclusive, and high-trust environment for its more than 1,600 U.S.-based employees. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. Share Bradford Health achieved certification with 67% of employees reporting a positive experience at work, surpassing the typical U.S.-based company average of 57%. Key areas of strength highlighted by employees include: 89% agree they are entrusted with significant responsibilities. 86% say their work has special meaning beyond being 'just a job,' and that they felt welcomed upon joining. 84% affirm they feel they make a difference in the organization. 82% report they can be themselves at work. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. 'We've built a culture where our people come first—where leaders exist to support, uplift, and empower our teams to live out our mission with purpose and compassion.' Great Place To Work® conducts its evaluations using its proprietary Trust Index™ survey and Trust Model™, which assess culture across five pillars: credibility, respect, fairness, pride, and camaraderie. About Bradford Health Services With 40 years of experience, Bradford Health Services operates addiction treatment centers in Alabama, Florida, Mississippi, North Carolina, Tennessee, and Texas. The organization is accredited by The Joint Commission and delivers evidence-based care at every stage of the recovery journey. About Great Place To Work® Certification Great Place To Work® Certification ™ is the gold standard for workplace culture recognition. Based on anonymous employee feedback, the certification recognizes organizations that foster high levels of trust, pride, and camaraderie.
Business Wire
2 days ago
- Business Wire
Arch Introduces New Supplemental Health Insurance Products to Help Bridge Coverage Gaps
HUNT VALLEY, Md.--(BUSINESS WIRE)--Arch Insurance's Accident & Health business unit, a leading provider of both business and consumer insurance products, is pleased to announce the launch of its new Individual Supplemental Health product suite. These products are designed to help individuals manage out-of-pocket expenses not typically covered by major medical plans, including deductibles, co-insurance and out-of-network charges through a variety of benefits including Accident Medical Expense, Hospital Indemnity, Critical Illness and Accidental Death. Arch's products provide an added layer of financial cushion when unexpected health events occur to individuals including employees, independent contractors, gig workers and association members. The products are available with no medical underwriting and are fully portable, allowing policyholders to keep their coverage through job or life changes. Arch's digital technology enables partners to generate quotes and complete enrollments in minutes. Arch's fully licensed call center provides sales and customer service support for both partners and clients. 'By offering access through our APEX™ digital platform or seamless API integration, we're making it easier than ever for our distribution partners to deliver these products efficiently and effectively to their clients,' said Jim Villa, Senior Vice President, Arch Accident & Health. For more information or to schedule a call to discuss how our individual supplemental health products can add value to your company, please visit our website or contact us at accidentandhealth@ About Arch Accident & Health Arch Accident & Health is a leading provider of innovative insurance solutions, committed to redefining industry standards through technological advancements and unparalleled client support. With a focus on excellence and a dedication to delivering value-driven products, Arch Accident & Health continues to lead the way in the insurance sector. About Arch Insurance North America Arch Insurance North America, part of Arch Capital Group Ltd., includes Arch's insurance operations in the United States and Canada. Business in the U.S. is written by Arch Insurance Company, Arch Specialty Insurance Company, Arch Property & Casualty Insurance Company and Arch Indemnity Insurance Company. Business in Canada is written by Arch Insurance Canada Ltd. About Arch Capital Group Ltd. Arch Capital Group Ltd., a publicly listed Bermuda exempted company with approximately $22.1 billion in capital at March 31, 2024, provides insurance, reinsurance and mortgage insurance on a worldwide basis through its wholly owned subsidiaries. Cautionary Note Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward−looking statements. This release or any other written or oral statements made by or on behalf of Arch Capital Group Ltd. and its subsidiaries may include forward−looking statements, which reflect the Company's current views with respect to future events and financial performance. All statements other than statements of historical fact included in or incorporated by reference in this release are forward−looking statements. Forward−looking statements can generally be identified by the use of forward−looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or their negative or variations or similar terminology. Forward−looking statements involve the Company's current assessment of risks and uncertainties. Actual events and results may differ materially from those expressed or implied in these statements. A non-exclusive list of the important factors that could cause actual results to differ materially from those in such forward-looking statements includes the following: adverse general economic and market conditions; increased competition; pricing and policy term trends; fluctuations in the actions of rating agencies and the Company's ability to maintain and improve its ratings; investment performance; the loss of key personnel; the adequacy of the Company's loss reserves, severity and/or frequency of losses, greater than expected loss ratios and adverse development on claim and/or claim expense liabilities; greater frequency or severity of unpredictable natural and man-made catastrophic events, including the effect of contagious diseases on our business; the impact of acts of terrorism and acts of war; changes in regulations and/or tax laws in the United States or elsewhere; ability to successfully integrate, establish and maintain operating procedures as well as integrate the businesses the Company has acquired or may acquire into the existing operations; changes in accounting principles or policies; material differences between actual and expected assessments for guaranty funds and mandatory pooling arrangements; availability and cost to the Company of reinsurance to manage our gross and net exposures; the failure of others to meet their obligations to the Company; an incident, disruption in operations or other cyber event caused by cyber attacks, the use of artificial intelligence technologies or other technology on the Company's systems or those of the Company's business partners and service providers, which could negatively impact the Company's business and/or expose the Company to litigation; and other factors identified in our filings with the U.S. Securities and Exchange Commission (SEC). The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with other cautionary statements that are included herein or elsewhere. All subsequent written and oral forward−looking statements attributable to us or persons acting on the Company's behalf are expressly qualified in their entirety by these cautionary statements. The Company's forward-looking statements speak only as of the date of this press release or as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward−looking statement, whether as a result of new information, future events or otherwise. Source — Arch Insurance North America Tag — arch-insurance
